Setting: Two tertiary academic centers. Patients: We enrolled children younger than 18 years who were admitted to the PICU within 24 hours after insertion of a central venous catheter. We excluded ...
People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...
Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...
Once-weekly prophylaxis with efanesoctocog alfa (Altuviiio) led to high sustained factor VIII activity and was effective in preventing bleeding among children with severe hemophilia A, the phase III ...
Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...
DUBLIN--(BUSINESS WIRE)--The "Hemophilia a (Factor Viii Deficiency) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report enhances the ...
But Why Tho? on MSN
REVIEW: ‘X-Factor’ Issue 8
X-Factor Issue 8 is published by Marvel Comics. Written by Mark Russell, art by Bob Quinn, colors by Jesus Aburtov and letter ...
Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec conferred sustained bleeding control at 2 years among a cohort of men with severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results